Propensity methods for multiple sclerosis: The devil is in the details

Affiliations

¹ Department of Neurology, Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic Foundation, Cleveland, OH, USA/Department of Epidemiology and Biostatistics, Case Western Reserve University, Cleveland, OH, USA ontaned@ccf.org.
² Department of Epidemiology and Biostatistics, Case Western Reserve University, Cleveland, OH, USA/Department of Medicine, Case Western Reserve University, Cleveland, OH, USA/Center for Health Care Research & Policy, MetroHealth Medical Center, Cleveland, OH, USA.

Editorial

Daniel Ontaneda et al. Mult Scler. 2016 Sep.

. 2016 Sep;22(10):1248-9.

doi: 10.1177/1352458516660390. Epub 2016 Jul 13.

¹ Department of Neurology, Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic Foundation, Cleveland, OH, USA/Department of Epidemiology and Biostatistics, Case Western Reserve University, Cleveland, OH, USA ontaned@ccf.org.
² Department of Epidemiology and Biostatistics, Case Western Reserve University, Cleveland, OH, USA/Department of Medicine, Case Western Reserve University, Cleveland, OH, USA/Center for Health Care Research & Policy, MetroHealth Medical Center, Cleveland, OH, USA.

No abstract available

Comment on

Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies.
Baroncini D, Ghezzi A, Annovazzi PO, Colombo B, Martinelli V, Minonzio G, Moiola L, Rodegher M, Zaffaroni M, Comi G. Baroncini D, et al. Mult Scler. 2016 Sep;22(10):1315-26. doi: 10.1177/1352458516650736. Epub 2016 May 26. Mult Scler. 2016. PMID: 27230789